Free Trial

Omeros (OMER) News Today

Omeros logo
$8.10 -1.73 (-17.60%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$8.11 +0.01 (+0.11%)
As of 10/17/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Why Is Omeros Dropping Today?

Omeros Corporation (OMER) — Shares moved sharply after a licensing deal and follow‑on analyst and media coverage. The near‑term rally was driven by a large Novo Nordisk agreement, while volatility and a subsequent gap down reflect profit‑taking and heavy intraday volume.

  • Positive Sentiment: Novo Nordisk licensed Omeros’ MASP‑3 inhibitor zaltenibart in a deal worth up to $2.1 billion (≈$340M upfront plus milestones). The transaction brings immediate non‑dilutive cash, validates Omeros’ MASP‑3 program, and creates material upside via milestones/royalties if development succeeds. Novo Nordisk snaps up Omeros’ rare disease asset for up to $2.1bn
  • Positive Sentiment: HC Wainwright raised near‑ and long‑term EPS forecasts and reiterated a Buy rating with a $20 target, signaling analyst confidence that the company’s pipeline and partner deal materially improve Omeros’ path to profitability. This supports higher valuation expectations over the next several years. FY2025 Earnings Estimate for Omeros Issued By HC Wainwright
  • Positive Sentiment: Omeros published peer‑reviewed data showing survival benefits with narsoplimab in TA‑TMA, strengthening the clinical and commercial story for its MASP‑2 program and adding credibility to the company’s complement‑pathway franchise. Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients
  • Neutral Sentiment: Wide media and analyst coverage (Seeking Alpha, Zacks, Blockonomi, Motley Fool) amplified investor attention and trading interest after the deal; coverage drove higher volume but is descriptive rather than new fundamental data. Omeros: Novo Nordisk's Licensing Deal Sends Shares Soaring, Makes Bull Case
  • Negative Sentiment: After an initial surge, shares later gapped down amid heavy trading and profit‑taking; MarketBeat flagged the gap‑down and asked whether investors should sell — signaling short‑term volatility risk despite the deal. Traders should expect large intraday swings. Omeros (NASDAQ:OMER) Shares Gap Down - Should You Sell?
Posted 1+ days agoAI Generated. May Contain Errors.

OMER Latest News

HC Wainwright Has Positive Outlook of Omeros FY2025 Earnings
Omeros (NASDAQ:OMER) Trading Down 13.7% - Time to Sell?
Omeros' (OMER) Buy Rating Reiterated at D. Boral Capital
Omeros (NASDAQ:OMER) Price Target Raised to $20.00
Omeros' (OMER) "Strong-Buy" Rating Reiterated at WBB Securities
Omeros (NASDAQ:OMER) Shares Gap Down - Should You Sell?
FY2025 Earnings Estimate for Omeros Issued By HC Wainwright
Pharmaceutical Stocks To Follow Now - October 15th
Novo Nordisk snaps up Omeros’ rare disease asset for up to $2.1bn
Omeros (NASDAQ:OMER) Shares Gap Up - Here's Why
Omeros Signs Major Deal with Novo Nordisk
Omeros (OMER) Receives a Buy from Intermonte
Omeros: Deja Vu All Over Again (Rating Downgrade)
Get Omeros News Delivered to You Automatically

Sign up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

OMER Media Mentions By Week

OMER Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

OMER
News Sentiment

0.50

0.48

Average
Medical
News Sentiment

OMER News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

OMER Articles
This Week

38

5

OMER Articles
Average Week

Get the Latest News and Ratings for OMER and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Omeros and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools


This page (NASDAQ:OMER) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners